ClinicalTrials.gg
Not yet recruitingNCT06009289Updated Aug 25, 2023

Light and Sleep Fragmentation

A Phase 4 interventional study of Light therapy in Sleep, Mild Cognitive Impairment and Mood Disorders, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by Stanford University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
65 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Cognitive Dysfunction by Stanford University — 3 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Stanford University.

Started
2026
the only one that year
Phase 4
Only one
of the 14
Registered
9th of 14
by date

Among the 14 studies in Cognitive Dysfunction by Stanford University, this one is the only one that started in 2026, is the only one in phase 4, and was the 9th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

3 of the 14 studies in Cognitive Dysfunction by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Cognitive Dysfunction by Stanford University, or all of them as a file.
02

Study summary

This trial will examine scheduled exposure to bright light in the morning and afternoon as a countermeasure to sleep fragmentation in older individuals with mild cognitive impairment.

03

Conditions studied

  • Sleep
  • Mild Cognitive Impairment
  • Mood Disorders
04

Who can participate

Ages eligible
65 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild Cognitive Impairment
  • Age >65

Exclusion criteria

Exclusion Criteria:

  • Severe depression
  • Unstable psychiatric or medical disease
  • Acute infection
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Standard of care

    One hour of daily bright light exposure beginning one hour after wake time.

    Behavioral: Light therapy

  • Experimental
    Stepped care

    One hour of daily bright light exposure in the afternoon

    Behavioral: Light therapy

Interventions

  • BehavioralLight therapy

    One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor

06

What researchers measure

Primary outcomes

  1. Sleep fragmentation

    24 hour sleep wake patterns will be quantitated with a non-parametric measure, intradaily variation

    Time frame: 4 weeks

Secondary outcomes

  1. Cognition

    Performance on the WAIS-4

    Time frame: 6 months

  2. Mood

    Geriatric Depression Scale, range: 0-15 with higher scores being associated with greater depressive symptomatology

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — After completion of study and publication of data, deidentified IPD will be uploaded to Dryad with documentation. Analytic code will be shared with Github

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: within six months after publication; no restrictions on duration of availability

Data sharing details ↗ · laneguides.stanford.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2028, 23 months later.

Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's planned 23 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Aug 24, 2023
StartEst.
Jun 1, 2026
Primary completionEst.
May 30, 2028
CompletionEst.
May 30, 2028
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06009289
Responsible party
Jamie M. Zeitzer, Ph.D. (Professor, Stanford University) — Principal investigator
First posted
Aug 24, 2023
Start date
Jun 1, 2026 (estimated)
Primary completion
May 30, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Aug 25, 2023

Study contacts

Renske Lok, PhD
Contact
rlok@stanford.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion